RegeneRx


News & Events

News Release Archive
Articles
DateTitle 
03/05/10Researchers Report that Thymosin beta 4 Improves Neurological Function after StrokePrinter Friendly Version
03/02/10RegeneRx Biopharmaceuticals' President and CEO to Present at 22nd Annual Roth Capital Growth Stock ConferencePrinter Friendly Version
02/26/10Researchers Report Novel Biological Properties of Fragments of Thymosin Beta 4Printer Friendly Version
02/08/10Researchers Report Elevated Levels of TB4 Levels Predict Patient Survival in Hepatitis B Virus-related Liver FailurePrinter Friendly Version
02/05/10Researchers Report that TB4 Increases Skeletal Muscle and May Have a Role in the Treatment of Duchenne Muscular DystrophyPrinter Friendly Version
01/21/10RegeneRx Biopharmaceuticals, Inc. Moving to New Corporate Office SpacePrinter Friendly Version
01/12/10NIH Awards Over $5,000,000 for TB4 Research in 2009/2010Printer Friendly Version
12/09/09RegeneRx Announces Final Clinical Results from Phase I Trial with RGN-352Printer Friendly Version
10/02/09Promising Clinical Data with RegeneRx's TB4 Drug Candidates Presented on Second Day of Thymosin MeetingPrinter Friendly Version
10/02/09Promising Clinical Data with RegeneRx's Tβ4 Drug Candidates Presented on Second Day of Thymosin MeetingPrinter Friendly Version
10/01/09Scientists Report Impressive Research Results with TB4 on First Day of Thymosin MeetingPrinter Friendly Version
10/01/09Scientists Report Impressive Research Results with Tβ4 on First Day of Thymosin MeetingPrinter Friendly Version
09/30/09RegeneRx Announces Offerings of Common Stock in Aggregate Amount of $4.7 MillionPrinter Friendly Version
09/29/09RegeneRx's TB4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal ModelPrinter Friendly Version
09/29/09RegeneRx's Tβ4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal ModelPrinter Friendly Version
09/24/09RegeneRx Biopharmaceuticals to Present Several Papers at Second International Symposium on Thymosins in Health and DiseasePrinter Friendly Version
09/04/09RegeneRx President and CEO to Speak at Rodman & Renshaw Annual Global Investment ConferencePrinter Friendly Version
08/24/09RegeneRx Receives Notice of Allowance in Europe for Key Patent Related to Inhibition and Reversal of Skin AgingPrinter Friendly Version
06/29/09NYSE Amex Accepts RegeneRx Plan of CompliancePrinter Friendly Version
06/22/09RegeneRx Working with U.S. Military to Test Tβ4 Against Exposure to Chemical Agents in the EyePrinter Friendly Version
06/12/09RegeneRx Receives Australian Patent for Compositions and Methods for Delivering Tβ4 and Its Analogues and DerivativesPrinter Friendly Version
05/04/09RegeneRx Receives Australian Patent for Treating Eye Disorders with Tβ4Printer Friendly Version
04/30/09RegeneRx Receives Listing Notice from NYSE AmexPrinter Friendly Version
04/13/09Tβ4 Identified as Key Molecule Capable of Triggering Stem Cells to Repair Damaged Adult HeartPrinter Friendly Version
04/13/09RegeneRx Announces Financing Transaction and Cost Reduction ProgramPrinter Friendly Version
04/02/09Ophthalmology Times Publishes Article on RGN-259 and Corneal Wound HealingPrinter Friendly Version
03/26/09RegeneRx Reports Phase II Venous Stasis Trial ResultsPrinter Friendly Version
Receive E-mail AlertsE-mail Alerts
 Upcoming Events
There are currently no events scheduled.
 Past Events
DateTitle
09/10/09 12:30 p.m. ET
RegeneRx Biopharmaceuticals, Inc. at Rodman & Renshaw Annual Global Investment Conference
LocationNew York, NY
10/30/08 11:00 a.m. PT
RegeneRx Biopharmaceuticals, Inc. at 7th Annual BIO Investor Forum
LocationSan Francisco, CA
04/02/08 3:00 p.m. ET
Q4 2007 RegeneRx Biopharmaceuticals, Inc. Earnings Conference Call
07/31/07 4:30 p.m. ET
RegeneRx Biopharmaceuticals, Inc. to Provide Update on Clinical Trials Program
06/07/07 10:00 a.m. ET
RegeneRx Biopharmaceuticals, Inc. Shareholders Meeting
Location2550 M Street, NW
, DC
04/02/07 3:00 p.m. ET
Q4 2006 RegeneRx Biopharmaceuticals, Inc. Earnings Conference Call
07/25/06 10:00 a.m. ET
RegeneRx Biopharmaceuticals, Inc. Annual General Shareholders Meeting
Location2550 M St, NW
Washington, DC
03/31/06 11:00 a.m. ET
Q4 2005 RegeneRx Biopharmaceuticals, Inc. Earnings Conference Call
03/31/06
Q4 2005 RegeneRx Biopharmaceuticals, Inc. Earnings Release

     
home|Contact Us|Resources|Site Map|
Search